Clinical Study of Spectral CT
Prospective, Single-center, Randomized Clinical Study Evaluating the Image Quality of Chest and Abdominal Scans Using Low-Dose Acquisition With Spectral Precise Image (SPI) Intelligent Denoising Versus Routine-Dose Acquisition Reconstructed With iDose4.
1 other identifier
interventional
80
1 country
1
Brief Summary
This study will prospective enroll 80 subjects to evaluate the comparison of image quality, proportion of high-quality images, and image noise between the Spectral Precise Image (SPI) intelligent denoising for low-dose scans on the Spectral CT Verida system and iDose4 reconstructions after chest and abdomen low-dose and routine-dose scans.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 3, 2026
CompletedFirst Posted
Study publicly available on registry
August 11, 2026
CompletedStudy Start
First participant enrolled
September 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2027
Study Completion
Last participant's last visit for all outcomes
September 1, 2027
August 11, 2026
July 1, 2026
1 year
August 3, 2026
August 10, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
The rate of good-excellent scores ≥3
Image quality will be assessed by 2 radiologists using Likert-scale on a range from 1(poor) to 5(Excellent),and calculate the rate of ≥3 with FAS,PSS SS as the datasets analysis.
From date of image reconstruction until the date of image reading completion, anticipated 1Week.
Secondary Outcomes (1)
Image Noise
From Image reconstruction to image noise recording finished,estimate 1Week.
Study Arms (2)
Normal Dose
OTHERLow Dose
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years.
- kg/m² ≤ BMI \< 28 kg/m².
- Conscious, able to cooperate, and competent to perform study procedures.
- Voluntarily agrees to participate in this clinical study and has signed the informed consent form.
- Women of childbearing potential must have a negative pregnancy test and have no plans to become pregnant during the next 6 months.
You may not qualify if:
- Persons without full civil capacity.
- Pregnant or breastfeeding women.
- Any other conditions that, in the investigator's judgment, make the subject unsuitable for participation in this clinical study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Philips Clinical & Medical Affairs Globallead
- Ruijin Hospitalcollaborator
Study Sites (1)
No. 197 Ruijin 2nd road, Huangpu District
Shanghai, Shanghai Municipality, 200020, China
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 3, 2026
First Posted
August 11, 2026
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2027
Last Updated
August 11, 2026
Record last verified: 2026-07